Pharmafile Logo
Pharmafocus logo
Advanced Search

Arzerra

Showing 15 posts of 19 posts found.

novartis_outside_1

Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis

September 3, 2019
Manufacturing and Production, Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, pharma

New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment …

News
cancer

Genmab’s CLL drug gets negative opinion from EMA committee

June 24, 2016
Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer

Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …

News
clinical_trial_4

Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration

June 2, 2016
Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III

Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …

News
arzerra_novartis

Novartis seeks expanded Arzerra use in US

March 11, 2016
Research and Development Arzerra, CLL, FDA, Genmab, Novartis

Novartis has submitted a supplemental Biologics License Application (sBLA) to the US FDA for the use of Arzerra (ofatumumab) in …

News

Genmab ends ofatumumab trials for autoimmune conditions; to focus on multiple sclerosis

March 9, 2016
Research and Development Arzerra, GSK

Danish drug-company Genmab (Nasdaq Copenhagen: GEN) said it will discontinue the late-stage trials for Arzerra (ofatumumab) to develop a treatment for …

News
Arzerra

Genmab pulls plug on Phase III Arzerra trial

November 24, 2015
Manufacturing and Production, Research and Development Arzerra, Genmab, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma, ofatumumab, phase III, phase III failure

Genmab has stopped a Phase III study of its CD20-directed monoclonal antibody Arzerra, after it was shown to be unlikely …

News
arzerra image

Trial results back NICE decision on Novartis cancer drug

April 15, 2015
Sales and Marketing Arzerra, Cancer, NHS, NICE, chemo, chlorambucil, fludarabine, leukaemia, ofatumumab

Treatment with Arzerra improves survival in people with chronic lymphocytic leukaemia (CLL) according to study results that back NICE’s decision …

News
GSK image

NICE backs GSK’s leukaemia drug Arzerra following price cut

November 4, 2014
Sales and Marketing Arzerra, CLL, GSK, NHS, NICE, leukaemia

NICE has recommended that GlaxoSmithKline’s Arzerra be prescribed under the NHS for patients with chronic lymphocytic leukaemia (CLL), after a …

News
GSK logo

GSK’s Arzerra fails in lymphoma

May 21, 2014
Research and Development, Sales and Marketing Arzerra, GSK, Genmab, non-Hodgkin lymphoma

News
Roche logo

FDA approves Roche’s new leukemia drug

November 4, 2013
Research and Development, Sales and Marketing Arzerra, CLL, FDA, GSK, Roche, chronic lymphocytic leukaemia

News
gsk image

US regulator ponders Arzerra

October 22, 2013
Sales and Marketing Arzerra, CLL, FDA, GSK

GlaxoSmithKline and Genmab have submitted their blood cancer drug Arzerra to the FDA as a first-line treatment for chronic lymphocytic …

News
Arzerra image

EMA gets first line Arzerra submission

October 7, 2013
Sales and Marketing Arzerra, GSK, Genmab, blood cancer

GlaxoSmithKline and Genmab have submitted their blood cancer drug Arzerra to the European Medicines Agency (EMA) in a first line …

News
gsk_hedge

GSK/Genmab leukaemia drug joins FDA speed lane

September 16, 2013
Research and Development, Sales and Marketing Arzerra, GSK, Genmab, Levact, MabThera, chronic lymphocytic leukaemia

News

NICE refuses cancer drugs Arzerra, Torisel and Levact

October 27, 2010
Sales and Marketing Arzerra, GSK, NICE, Napp Pharmaceuticals, Pfizer, Torisel, Treanda, cancer drugs

NICE has refused to recommend a trio of cancer drugs for NHS use – but in two cases says this …

News

GSK switches to subcutaneous route for antibody

September 16, 2010
Research and Development Arzerra, Genmab, GlaxoSmithKline, ofatumumab

GlaxoSmithKline says it will switch development of a new antibody treatment to a subcutaneous injection, to make it more commercially …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024